| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Daniela Furrer, Karin Kaufmann, Flurin Tschuor, Claudia E Reusch, Thomas A Lut. The dipeptidyl peptidase IV inhibitor NVP-DPP728 reduces plasma glucagon concentration in cats. Veterinary journal (London, England : 1997). vol 183. issue 3. 2010-04-23. PMID:19128990. |
glucagon-like peptide-1 (glp-1) analogues and inhibitors of its degrading enzyme, dipeptidyl peptidase iv (dppiv), are interesting therapy options in human diabetics because they increase insulin secretion and reduce postprandial glucagon secretion. |
2010-04-23 |
2023-08-12 |
human |
| A M C Simonis-Bik, E M W Eekhoff, M H M de Moor, M H H Kramer, D I Boomsma, R J Heine, J M Dekker, J A Maassen, L M 't Hart, M Diamant, E J C de Geu. Genetic influences on the insulin response of the beta cell to different secretagogues. Diabetologia. vol 52. issue 12. 2010-04-23. PMID:19802603. |
the aim of the present study was to estimate the heritability of the beta cell insulin response to glucose and to glucose combined with glucagon-like peptide-1 (glp-1) or with glp-1 plus arginine. |
2010-04-23 |
2023-08-12 |
Not clear |
| Satish K Gar. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. Diabetes technology & therapeutics. vol 12. issue 1. 2010-04-23. PMID:20082581. |
the position and clinical efficacy of the glp-1 mimetics are less well understood, however, and how they should be best used in the context of the established clinical efficacy of long-acting insulin analogs is yet to be defined. |
2010-04-23 |
2023-08-12 |
Not clear |
| Satish K Gar. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. Diabetes technology & therapeutics. vol 12. issue 1. 2010-04-23. PMID:20082581. |
the aim of this review is to provide a summary of the efficacy, safety, and weight changes associated with long-acting insulin analogs (insulin glargine and insulin detemir) and two glp-1 mimetics (exenatide and liraglutide). |
2010-04-23 |
2023-08-12 |
Not clear |
| Satish K Gar. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. Diabetes technology & therapeutics. vol 12. issue 1. 2010-04-23. PMID:20082581. |
this literature review demonstrates that glp-1 and basal insulin therapies are effective treatment options for insulin-naïve patients with suboptimal glycemic control with oral hypoglycemic agents. |
2010-04-23 |
2023-08-12 |
Not clear |
| Satish K Gar. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. Diabetes technology & therapeutics. vol 12. issue 1. 2010-04-23. PMID:20082581. |
there are potential advantages of basal insulin and glp-1 therapies in particular populations of patients. |
2010-04-23 |
2023-08-12 |
Not clear |
| Angela M Abbatecola, Giuseppe Paoliss. Diabetes care targets in older persons. Diabetes research and clinical practice. vol 86 Suppl 1. 2010-04-23. PMID:20115930. |
available anti-diabetic oral drugs include insulin secretagogues (meglitinides and sulfonylureas), biguanides (metformin) alpha-glucosidase inhibitors, thiazolidinediones (tzds) and newly introduced glucagon-like peptide-1 (glp-1) analogues and inhibitors of glp-1 degrading enzyme dipeptidyl peptidase-4 (dpp-4). |
2010-04-23 |
2023-08-12 |
Not clear |
| Raquel N Faradji, Tatiana Froud, Shari Messinger, Kathy Monroy, Antonello Pileggi, Davide Mineo, Thipaporn Tharavanij, Armando J Mendez, Camillo Ricordi, Rodolfo Alejandr. Long-term metabolic and hormonal effects of exenatide on islet transplant recipients with allograft dysfunction. Cell transplantation. vol 18. issue 10. 2010-04-13. PMID:20003758. |
exenatide, a glp-1 agonist, increases insulin and decreases glucagon secretion and has potential for beta-cell regeneration. |
2010-04-13 |
2023-08-12 |
human |
| M J Riedel, D F Gaddy, A Asadi, P D Robbins, T J Kieffe. DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes. Gene therapy. vol 17. issue 2. 2010-04-12. PMID:19865180. |
glucagon-like peptide-1 (glp-1) is an incretin hormone that performs a wide array of well-characterized antidiabetic actions, including stimulation of glucose-dependent insulin secretion, upregulation of insulin gene expression and improvements in beta-cell survival. |
2010-04-12 |
2023-08-12 |
mouse |
| G Mingrone, L Castagneto-Gisse. Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery. Diabetes & metabolism. vol 35. issue 6 Pt 2. 2010-04-12. PMID:20152737. |
in fact, increased glp-1 plasma levels stimulate insulin secretion and suppress glucagon secretion, thereby improving glucose metabolism. |
2010-04-12 |
2023-08-12 |
human |
| A-J Scheen, J De Flines, A De Roover, N Paquo. Bariatric surgery in patients with type 2 diabetes: benefits, risks, indications and perspectives. Diabetes & metabolism. vol 35. issue 6 Pt 2. 2010-04-12. PMID:20152741. |
indeed, increased levels of glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) may lead to improved beta-cell function and insulin secretion as well as reduced insulin resistance associated with weight loss. |
2010-04-12 |
2023-08-12 |
Not clear |
| A E Relling, J L Pate, C K Reynolds, S C Loerc. Effect of feed restriction and supplemental dietary fat on gut peptide and hypothalamic neuropeptide messenger ribonucleic acid concentrations in growing wethers. Journal of animal science. vol 88. issue 2. 2010-04-09. PMID:19897637. |
on d 8, 15, 22, and 29, bw was measured before feeding, and 6 h after feeding, blood samples were collected for plasma measurement of insulin, glp-1, cck, ghrelin, glucose-dependent insulinotropic polypeptide, oxyntomodulin, glucose, and nefa concentrations. |
2010-04-09 |
2023-08-12 |
Not clear |
| A E Relling, J L Pate, C K Reynolds, S C Loerc. Effect of feed restriction and supplemental dietary fat on gut peptide and hypothalamic neuropeptide messenger ribonucleic acid concentrations in growing wethers. Journal of animal science. vol 88. issue 2. 2010-04-09. PMID:19897637. |
we conclude that insulin, ghrelin, cck, and glp-1 may regulate dmi in sheep by regulating the hypothalamic gene expression of npy, agrp, and pomc. |
2010-04-09 |
2023-08-12 |
Not clear |
| Meena Asmar, Patricia V Højberg, Carolyn F Deacon, Kristine Hare, Jens J Holst, Sten Madsba. Pancreatic beta-cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes. Regulatory peptides. vol 160. issue 1-3. 2010-04-09. PMID:20005261. |
this study investigated the effects of strict glycaemic control on beta-cell function in nine obese subjects with type 2 diabetes (t2dm), using graded glucose infusions together with infusions of saline or glp-1 before (hba(1)c: 8.0+/-0.4%) and after four weeks of near-normalization of blood glucose (bg) using insulin (mean diurnal bg: 6.4+/-0.3 mmol/l; hba(1)c: 6.6+/-0.3%). |
2010-04-09 |
2023-08-12 |
human |
| Meena Asmar, Patricia V Højberg, Carolyn F Deacon, Kristine Hare, Jens J Holst, Sten Madsba. Pancreatic beta-cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes. Regulatory peptides. vol 160. issue 1-3. 2010-04-09. PMID:20005261. |
proinsulin responses to glp-1 were unchanged, but amylin and c-peptide aucs increased (p<0.05) after insulin treatment, and auc amylin/c-peptide ratios rose to control levels. |
2010-04-09 |
2023-08-12 |
human |
| Josina M Rijkelijkhuizen, Kelly McQuarrie, Cynthia J Girman, Peter P Stein, Andrea Mari, Jens J Holst, Giel Nijpels, Jacqueline M Dekke. Effects of meal size and composition on incretin, alpha-cell, and beta-cell responses. Metabolism: clinical and experimental. vol 59. issue 4. 2010-04-07. PMID:19846181. |
the incretins glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) regulate postprandial insulin release from the beta-cells. |
2010-04-07 |
2023-08-12 |
human |
| Josina M Rijkelijkhuizen, Kelly McQuarrie, Cynthia J Girman, Peter P Stein, Andrea Mari, Jens J Holst, Giel Nijpels, Jacqueline M Dekke. Effects of meal size and composition on incretin, alpha-cell, and beta-cell responses. Metabolism: clinical and experimental. vol 59. issue 4. 2010-04-07. PMID:19846181. |
non-model-based and model-based estimates of beta-cell function and incremental areas under the curve of glucose, insulin, c-peptide, glucagon, glp-1, and gip were calculated. |
2010-04-07 |
2023-08-12 |
human |
| Nigel Irwin, Peter R Flatt, Steven Patterson, Brian D Gree. Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline. European journal of pharmacology. vol 628. issue 1-3. 2010-04-05. PMID:19917278. |
dmb significantly stimulated in vitro insulin secretion from brin-bd11 cells but with decreased molar potency compared to native glp-1 or related mimetics. |
2010-04-05 |
2023-08-12 |
mouse |
| Guang-ming Song, Yi Huan, Su-juan Sun, Yue-teng Chen, Quan Liu, Zhu-fang She. Biological activity of EXf, a peptide analogue of exendin-4. European journal of pharmacology. vol 628. issue 1-3. 2010-04-05. PMID:19919832. |
exf activated the camp response element (cre) of the rat insulin i gene promoter (rip1) gfp-construct in a dose-dependent manner in the cultured mouse insulinoma cell line, termed nit-1, and this agonist activity was blocked by the glucagon-like peptide 1 (glp-1) receptor antagonist exendin(9-39). |
2010-04-05 |
2023-08-12 |
mouse |
| Mads Halbirk, Helene Nørrelund, Niels Møller, Jens Juul Holst, Ole Schmitz, Roni Nielsen, Jens Erik Nielsen-Kudsk, Søren Steen Nielsen, Torsten Toftegaard Nielsen, Hans Eiskjaer, Hans Erik Bøtker, Henrik Wigger. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. American journal of physiology. Heart and circulatory physiology. vol 298. issue 3. 2010-04-02. PMID:20081109. |
glp-1 increased insulin (90 +/- 17 pmol/l vs. 69 +/- 12 pmol/l; p = 0.025) and lowered glucose levels (5.2 +/- 0.1 mmol/l vs. 5.6 +/- 0.1 mmol/l; p < 0.01). |
2010-04-02 |
2023-08-12 |
Not clear |